News
Article
Author(s):
Zelsuvmi is the first FDA-approved at-home treatment for molluscum contagiosum, now available for patients aged ≥1 via retail and mail-order pharmacies.
Pelthos Therapeutics announced today it has launched berdazimer topical gel, 10.3% (Zelsuvmi),1 a first-in-class, nitric oxide-releasing gel approved for at-home application in adults and children aged 1 year and older. The launch marks the first time dermatology clinicians can prescribe an FDA-approved topical molluscum treatment that does not require in-office procedures.
Molluscum contagiosum affects an estimated 16.7 million individuals annually in the US, with 6 million new cases each year, primarily in pediatric populations.1 Until recently, the only FDA-approved treatment option was cantharidin 0.7% (Ycanth; Verrica Pharmaceuticals), an in-office applied solution approved by the FDA in 2023.2 The introduction of Zelsuvmi represents a convenient option for patients that can be self-applied once daily by patients themselves, parents, or caregivers at home or on the go.
“We believe that the commercial launch of Zelsuvmi marks a significant advancement for patients with molluscum and their caregivers, who previously lacked an at-home treatment option for this burdensome skin infection,” said Scott Plesha, CEO of Pelthos, in a news release.1
Clinical data from the B-SIMPLE4 trial (NCT04535531), the largest randomized trial for molluscum to date, was published in JAMA Dermatology.3 The trial enrolled 891 patients in a multicenter, randomized, double-blind, vehicle-controlled format.
Key findings at week 12 included complete lesion clearance in 32.4% of patients using berdazimer vs 19.7% in the vehicle group. Results observed in as early as 2 weeks for some patients, and berdazimer was well-tolerated safety profile with primarily mild local skin reactions.
Zelsuvmi’s path to availability began when the FDA accepted a New Drug Application (NDA) for berdazimer gel, 10.3%, developed using Pelthos’ proprietary Nitricil technology, which ensures controlled nitric oxide release to enhance antiviral and antimicrobial activity.4
Zelsuvmi received FDA approval as a novel drug, being the first-ever molluscum therapy authorized for at-home prescription use in both children and adults aged ≥1 year.5
“The approval of [berdazimer gel] Zelsuvmi is a breakthrough, marking the first time that clinicians can treat molluscum with an efficacious topical prescription medication that is applied by the patient, or a family member,” said Mark D. Kaufmann, MD, FAAD, clinical professor of dermatology in the department of dermatology at the Icahn School of Medicine at Mount Sinai in New York, New York and past president of the American Academy of Dermatology, in a press release at the time of the approval.5
Read more from Dermatology Times.
To bring Zelsuvmi to market, Ligand Pharmaceuticals launched Pelthos Therapeutics, a commercial-stage biopharmaceutical company focused on advancing Nitricil-based dermatologic treatments.6 Under CEO Scott Plesha, Pelthos prepared to scale Zelsuvmi through both traditional pharmacy and mail-order channels.
To accelerate commercial rollout, Pelthos merged with Channel Therapeutics, backed by a $50 million investment from Ligand and strategic partners including Murchinson.7 The move created a newly-formed, publicly-traded entity focused on expanding both Zelsuvmi and a pipeline of sodium channel inhibitors for pain disorders.
With pharmacy and mail-order distribution infrastructure in place, Zelsuvmi officially becomes available via prescription nationwide in retail pharmacies, ASPN pharmacy services, and home-delivery options.1
Prior to Zelsuvmi’s approval, treatment of molluscum relied primarily on procedural interventions or unregulated compounded therapies.1 The introduction of berdazimer gel offers a topical, standardized therapy that expands patient care beyond the office.
“Many parents delay seeking treatment for their children’s uncomfortable lesions because current procedural treatments and frequent office visits can be inconvenient, while therapeutic options are limited. Untreated molluscum can spread throughout the child’s body but also to other family members,” said Nanette Silverberg, MD, chief of pediatric dermatology at the Mount Sinai Health System.1 “A safe and effective topical gel for molluscum, like Zelsuvmi, which can be applied at home or on the go, would make a significant difference for this young patient population and address a serious, unmet medical need.”
With Zelsuvmi now on the market, Pelthos aims to build further momentum by exploring the Nitricil platform’s potential in other dermatologic indications.
References
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.